SCYNEXIS, Inc.’s SEC filings document a biotechnology company with clinical-stage development programs in rare kidney disease and antifungal medicine. Its reports and current-event filings cover the acquired PXL-770, now SCY-770, AMPK activator assets for ADPKD; SCY-247 clinical and regulatory disclosures; and license arrangements involving ibrexafungerp and BREXAFEMME® with GSK.
SCYNEXIS filings also describe common-stock capitalization, material agreements, risk factors, operating and financial results, and Nasdaq-listed common stock. Proxy materials and Form 8-K reports cover shareholder voting matters, governance, board composition, executive compensation, auditor ratification, and proposed certificate-amendment matters affecting the company’s equity structure.
SCYNEXIS, Inc. (SCYX) reported a planned transition in its finance leadership, with longtime Chief Financial Officer Ivor Macleod retiring and ceasing to serve as CFO, principal financial officer and principal accounting officer effective September 9, 2026, while remaining through October 9, 2026 to support a smooth transition. The company appointed Sanjay Subramanian as its new Chief Financial Officer effective September 9, 2026, also designating him as principal financial officer and principal accounting officer under an employment agreement.
Subramanian’s package includes a $500,000 annual base salary, a $20,000 sign-on bonus, and an annual performance bonus opportunity of up to 40% of base salary, plus a stock option for 100,000 shares of SCYNEXIS common stock at a $4.91 per-share exercise price vesting over four years. The agreement provides severance protections, including salary continuation, equity vesting acceleration, and COBRA benefits for nine months, or 18 months in connection with certain terminations within 12 months after a change of control.
SCYNEXIS, Inc. received an amended Schedule 13G from CVI Investments, Inc. and Heights Capital Management, Inc., reporting beneficial ownership of SCYNEXIS common stock. The Reporting Persons collectively report beneficial ownership of 615,522 Shares, representing 5.9% of the outstanding common stock as of June 30, 2026.
The position consists of 150,551 Shares of common stock and additional Shares issuable upon exercise of warrants, which are subject to 4.99% and 9.99% beneficial ownership limitations. Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and may exercise shared voting and dispositive power over these Shares, while both entities disclaim beneficial ownership beyond their pecuniary interest.
Great Point Partners, LLC, together with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, reports beneficial ownership of 4,076,068 shares of SCYNEXIS, Inc. common stock, representing 9.99% of the class based on 9,930,329 shares outstanding after a 1-for-8 stock split effective June 1, 2026.
The position is held through Biomedical Value Fund, L.P. and Biomedical Offshore Value Fund, Ltd., including common shares and warrant shares limited by a 9.99% Beneficial Ownership Cap on warrant exercises. Great Point acts as investment manager to the funds; Dr. Jay and Ms. Nordahl may be deemed beneficial owners but each disclaims ownership except to the extent of pecuniary interest.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 1,041,824 shares of SCYNEXIS, Inc. common stock, including 498,346 shares issuable upon exercise of warrants. This position represents 9.99% of the outstanding common stock, based on approximately 9,930,329 shares outstanding after giving effect to a one-for-eight reverse stock split effective May 29, 2026.
All 1,041,824 shares are reported with shared voting and dispositive power and no sole voting or dispositive power. The shares are directly held by Adage Capital Partners, L.P., with Adage Capital Management, L.P. as investment manager and Messrs. Atchinson and Gross reporting through their roles in affiliated entities.
Scynexis, Inc., a clinical-stage biotech focused on rare kidney disease and invasive fungal infections, reported a Q2 2026 net income of $7.4 million, versus a loss a year earlier, largely driven by a $14.2 million noncash gain from warrant liability revaluation. Operating performance remained negative, with Q2 license revenue from its GSK agreement at $0.2 million and an operating loss of $7.8 million.
For the first six months of 2026, Scynexis recorded a net loss of $13.9 million on $0.2 million in revenue, as it increased investment in its pipeline. Research and development expense rose to $16.2 million, including an $8.0 million in-process R&D charge tied to acquiring the SCY-770 AMPK activator program for Autosomal Dominant Polycystic Kidney Disease. SG&A expenses were $8.7 million.
Liquidity improved following a March 2026 private placement that generated $40.0 million gross and $36.9 million net proceeds. As of June 30 2026, cash, cash equivalents and investments totaled $71.1 million, with total assets of $75.0 million and stockholders’ equity of $66.9 million. Management states these resources are sufficient to fund ongoing operations for at least 12 months and believes they extend the runway into 2029. A one-for-eight reverse stock split and subsequent authorized share increase also helped regain and support Nasdaq listing compliance.
Federated Hermes, Inc. and related parties report holdings in SCYNEXIS, Inc. common stock. The group, including Federated Hermes, Inc., the Voting Shares Irrevocable Trust, and Thomas R., Ann C., and J. Christopher Donahue, reports beneficial ownership of 441,658 shares of SCYNEXIS common stock, representing 4.03% of the class as of June 30, 2026.
The Voting Shares Irrevocable Trust has sole voting and dispositive power over these shares. The individual Donahues report shared voting and dispositive power over the same 441,658 shares. All reporting persons state, pursuant to Rule 13d-4, that the filing should not be construed as an admission of beneficial ownership and expressly disclaim beneficial ownership of the securities held by the managed funds.
SCYNEXIS INC ownership update: Federated Hermes, Inc. and related parties report 55,207 shares of Common Stock, representing 4.45% of the class as shown on the cover pages. The filing is an amendment (No. 17) to a Schedule 13G/A and includes a Rule 13d-4 disclaimer regarding beneficial ownership.
SCYNEXIS INC director Brian Philippe Tinmouth received new equity awards. On June 26, 2026, he was granted 2,875 shares of Common Stock as a restricted stock unit award, with all shares vesting on the first anniversary of the grant if he continues serving as a non-employee director.
He was also granted a stock option for 2,875 shares of Common Stock at an exercise price of $3.85 per share, expiring on June 25, 2036, which likewise vests in full after one year of continued service. Following the grant, he directly holds 12,125 shares of Common Stock. The share amounts reflect a 1-for-8 reverse stock split effective on May 29, 2026.
Macdonald Guy reported acquisition or exercise transactions in this Form 4 filing.
SCYNEXIS director Guy Macdonald received equity compensation on June 26, 2026, consisting of 2,875 restricted stock units and a stock option for 2,875 shares of common stock at $3.85 per share. Both awards vest in full on the first anniversary of grant if he continues serving as a non-employee director. Following the grant, he directly holds 12,625 common shares. All share amounts reflect SCYNEXIS’s 1-for-8 reverse stock split effective May 29, 2026.
SCYNEXIS Inc director Armando Anido reported receiving equity-based compensation. He was granted 2,875 shares of Common Stock as restricted stock units and 2,875 stock options, both at no cost to him. The options have an exercise price of $3.85 per share and expire on June 25, 2036.
All 2,875 restricted stock units and the 2,875 options vest 100% on the first anniversary of the grant date, provided he continues serving as a non-employee director on that vesting date. After these grants, Anido directly holds 11,750 Common shares and 2,875 options. The share amounts reflect a 1-for-8 reverse stock split effective May 29, 2026.